This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Mercantile Court In Spain Rules In ZELTIQ® Aesthetics Patent Infringement Lawsuit Against Clinipro

ZELTIQ ® Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that the Mercantile Court in Spain rendered its ruling on the merits of ZELTIQ’s and Massachusetts General Hospital’s (MGH) request for a permanent injunction against Clinipro’s LipoCryo device based on Clinipro’s infringement of two European patents owned by MGH and globally licensed exclusively to ZELTIQ and denied the request.

ZELTIQ is a global medical device company that has developed an innovative, noninvasive, clinically proven procedure that selectively reduces fat through controlled cooling. Its CoolSculpting ® technology is protected by numerous patents and trademarks around the world.

ZELTIQ and MGH filed suit against Clinipro in March 2012 alleging infringement by Clinipro of two European patents licensed by ZELTIQ from MGH and requested an injunction against further sales of Clinipro’s LipoCryo device. After hearing a petition in April 2012, the Mercantile Court granted ZELTIQ’s and MGH’s request for a preliminary injunction against further importation, distribution, and sales of Clinipro's LipoCryo device in Spain. The Mercantile Court subsequently scheduled a trial which was completed October 2012. ZELTIQ is being represented by Salvador Ferrandis & Partners. The Mercantile Court’s ruling is fully appealable and affects only Clinipro’s activities in Spain.

ZELTIQ has also filed a separate patent infringement lawsuit against Clinipro in France. Veron & Associes is representing ZELTIQ and MGH in this matter and the trial is expected to begin in April.

“We are disappointed in the Mercantile Court’s decision as our legal team and outside counsel were anticipating that the Court would follow its previous decision of granting our request for a preliminary injunction,” commented Mark Foley, President and Chief Executive Officer of ZELTIQ. “ZELTIQ and MGH intend to appeal this ruling immediately and, along with our outside counsel, we are confident that we will ultimately prevail. We remain steadfast in our commitment to vigorously enforce our intellectual property rights and will continue to partner with MGH to aggressively assert our rights.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,185.07 -103.56 -0.57%
S&P 500 2,105.08 -12.31 -0.58%
NASDAQ 4,971.2270 -36.8690 -0.74%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs